首页> 外文期刊>Molecular Therapy - Methods & Clinical Development >In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies
【24h】

In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies

机译:问题:基于细胞疗法的临床前安全药理学和毒理学研究的科学价值

获取原文
           

摘要

A new cell-based medicinal product containing human regulatory macrophages, known as Mreg_UKR, has been developed and conforms to expectations of a therapeutic drug. Here, Mreg_UKR was subjected to pharmacokinetic, safety pharmacology, and toxicological testing, which identified no adverse reactions. These results would normally be interpreted as evidence of the probable clinical safety of Mreg_UKR; however, we contend that, owing to their uncertain biological relevance, our data do not fully support this conclusion.
机译:已经开发出一种新的含有人调节性巨噬细胞的基于细胞的药物,称为Mreg_UKR,它符合治疗药物的期望。在这里,Mreg_UKR经过了药代动力学,安全药理学和毒理学测试,未发现不良反应。这些结果通常被解释为Mreg_UKR可能的临床安全性的证据。然而,我们认为,由于它们不确定的生物学相关性,我们的数据不能完全支持这一结论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号